BMJ openHumansTyphoid-Paratyphoid VaccinesDouble-Blind MethodParatyphoid FeverSalmonella paratyphi A
Phase II multicentre double-blind randomised controlled trial of a Bivalent VaccInation against Salmonella Typhi and Paratyphi A (BiVISTA) using a controlled human infection model of paratyphoid A infection: study protocol.
Margarete Paganotti Vicentine, Naina McCann, Oisin Hennigan, Noshi Maria, Claudia I Juarez Molina, Stanislava Koleva, Mohammod K Islam, Elizabeth Jones, Amy Flaxman, Nicole Day, Allison MacDonald, Mehreen Adnan, Nisha Singh, Sophie Vernon, Eleanor Wilson
Published: 202610.1136/bmjopen-2025-107608
Abstract
INTRODUCTION: Enteric fever, primarily caused by Salmonella enterica Typhi and Salmonella enterica Paratyphi A (SPA), is endemic mainly in South Asia, disproportionately affecting school-age children. Although typhoid conjugate vaccines (TCVs) are ef…
Preview only. Read the full abstract at the source